1. Home
  2. BMEA vs IDN Comparison

BMEA vs IDN Comparison

Compare BMEA & IDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.55

Market Cap

138.1M

Sector

Health Care

ML Signal

HOLD

Logo Intellicheck Inc.

IDN

Intellicheck Inc.

HOLD

Current Price

$8.13

Market Cap

153.8M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
IDN
Founded
2017
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
138.1M
153.8M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
BMEA
IDN
Price
$1.55
$8.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$9.83
$7.33
AVG Volume (30 Days)
1.9M
560.5K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
69.19
220.00
EPS
N/A
0.06
Revenue
N/A
$4,433,454.00
Revenue This Year
N/A
$12.54
Revenue Next Year
N/A
$15.32
P/E Ratio
N/A
$131.92
Revenue Growth
N/A
23.21
52 Week Low
$0.87
$2.47
52 Week High
$3.07
$9.08

Technical Indicators

Market Signals
Indicator
BMEA
IDN
Relative Strength Index (RSI) 43.52 59.20
Support Level $1.50 $4.50
Resistance Level $1.66 N/A
Average True Range (ATR) 0.16 0.42
MACD -0.05 -0.12
Stochastic Oscillator 0.00 39.87

Price Performance

Historical Comparison
BMEA
IDN

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About IDN Intellicheck Inc.

Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.

Share on Social Networks: